The WHO Data on Liver Cancer No One Is Talking About
Global liver cancer incidence has risen 75% over the past 20 years. We break down the WHO GLOBOCAN numbers — and what they mean for high-risk patients in the US right now.
A simple blood test detects hepatocellular carcinoma at Stage I & II — when survival rates are 11× higher. No hospital visit. Results in 24 hours.
MoleculeDx at a Glance — Updated in real time
Live Data Feed
Liver cancer has no reliable early-warning signs. Most patients feel fine until the disease is already advanced. The tools to screen for it have been inaccessible, invasive, or simply absent — until now.
Liver cancer (HCC) is one of the fastest-growing cancers in the United States. Yet most at-risk patients receive no routine surveillance. Why? Because existing screening methods are expensive, require hospital imaging, and demand repeat visits that patients — especially older adults — simply don’t complete.
The result: 75% of American liver cancer patients are diagnosed when curative treatment is no longer possible. This isn’t inevitable. It’s a gap we were built to close.
MoleculeDx’s simple blood test detects hepatocellular carcinoma (HCC) at Stage I & II — when it’s most treatable. No hospital visit. No biopsy. Results in 24 hours.
of liver cancers are detected at late stage — when survival drops from 34% to just 3%
UPMC Partnership: Walk-in testing now available at University of Pittsburgh Medical Center locations
Traditional liver cancer diagnosis involves invasive procedures with real risks. Our blood-based test is different — simple, safe, and accessible from home.
Fusion-detect™ outperforms every conventional liver cancer screening method currently available in the US.
Side-by-side accuracy metrics against the standard tests used in current clinical practice.
From booking to results, our entire process is designed for simplicity — especially for patients who find hospital visits difficult.
Schedule your at-home blood draw in minutes at booking.moleculedx.com. Pick a time that works for you.
A certified partner (Portamedic or Travalab) visits your home and collects a standard blood sample — usually under 10 minutes.
Our Fusion-detect™ platform screens your sample for liver cancer fusion gene biomarkers with industry-leading accuracy.
Receive your certified report digitally. If further follow-up is needed, we connect you with a specialist immediately.
Certified phlebotomist within 48 hrs
We’ve eliminated every barrier between you and early cancer detection. No hospital appointments. No waiting rooms. No travel. A trained professional comes directly to you.
Choose your date and 2-hour arrival window at booking.moleculedx.com — available 7 days a week, including evenings.
Our partners Portamedic and Travalab send nationally-certified phlebotomists to your door. The draw takes under 10 minutes.
Your sample is sealed and transported via cold-chain courier to our CLIA lab — maintaining integrity for the most accurate results.
A secure digital report lands in your inbox within 24 hours. No chasing down results — everything is clear and explained.
Fusion-detect™ is our proprietary genomic sequencing and AI analysis platform. It detects chromosomal fusion events — a hallmark of early-stage HCC — that are completely missed by conventional blood markers like AFP.
The platform has gone through four major AI training generations, each time dramatically improving detection accuracy. Here’s how AI transformed liver cancer detection:
Researchers identified 14 HCC-specific fusion gene events in circulating tumor DNA that appear up to 18 months before imaging-detectable tumors.
Initial ML classifier trained on 8,000 samples. Already outperformed AFP testing — but we knew we could go further.
A transformer-based neural network trained on 50,000+ annotated patient samples across 12 ethnic backgrounds for bias-free results.
Real-time ensemble AI with multi-biomarker fusion scoring, continuous learning pipeline, and <3% false positive rate. CLIA-certified and peer-review validated.
WHO and SEER data confirm liver cancer (HCC) is one of the world’s fastest-growing cancers. Without early detection tools, this trend means more late-stage diagnoses and preventable deaths.
Global liver cancer incidence has risen 75% over the past 20 years. We break down the WHO GLOBOCAN numbers — and what they mean for high-risk patients in the US right now.
If you have hepatitis, cirrhosis, or NAFLD, your doctor may be relying on ultrasound and AFP — tools that miss over 40% of early-stage HCC. Here’s what the evidence shows.
Machine learning models trained on fusion gene biomarkers are outperforming 40 years of conventional AFP testing — and changing what’s possible in oncology screening.
We’ve partnered with the best in US phlebotomy, clinical medicine, and health insurance to make testing seamless from booking to results.
One of America’s largest mobile health services networks — certified phlebotomists serving all 50 states, available 7 days a week for at-home blood draws.
Travalab’s mobile laboratory specialists provide concierge-level phlebotomy services, ensuring the highest sample quality and patient comfort from first contact.
University of Pittsburgh Medical Center — our exclusive clinical partner. UPMC patients and the public can walk in for testing at any UPMC facility.
Through our exclusive partnership with University of Pittsburgh Medical Center, you can walk into any UPMC facility today — no prior appointment required for testing referral.
No appointment needed at UPMC sites
UPMC oncologists review flagged results
Supported by UPMC clinical research program
Results flow directly into your UPMC medical record
A simple blood test could be the most important thing you do this year. Book online in 2 minutes and have a phlebotomist at your door within 48 hours.
© 2024 MoleculeDx Inc. All rights reserved.
This test is not a substitute for medical diagnosis. Consult your physician with all results.